Tags

Type your tag names separated by a space and hit enter

Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection.
J Vet Med B Infect Dis Vet Public Health. 2005 Sep-Oct; 52(7-8):362-5.JV

Abstract

In order to improve serodiagnostic methods for the determination of the state of human parovirus B19 infection, a new test system, recomLine Parvovirus, based on the use of recombinant antigens, has been developed and evaluated. The test system combines the advantages of enzyme-linked immunosorbent assay (ELISA) methods with those of the Western blot technique. For the recombinant line assay, five antigens of human parvovirus B19 that were recombinantly produced in Escherichia coli were applied directly on nitrocellulose membranes: VP2, the aminoterminal and the carboxyterminal domain of VP1 (VP-N and VP-C), VP-1S another fragment of VP-N and NS1. In addition, empty virus particles isolated from eukaryotic cell cultures were also applied. The recombinant-line assay was used to detect human IgG and IgM antibodies directed against human parvovirus B19. In addition, the avidity of the IgG antibodies was investigated. The recombinant line assay was evaluated using 87 human serum samples of patients recently infected with human parvovirus B19 including 10 samples of three infection time courses and 100 serum samples of healthy blood donors. All results were compared with commercially available ELISAs. In the case of discrepancies, Western blot analysis was performed. The data revealed the recombinant line assay to be highly sensitive and specific. The individual determination of the human immune response against several recombinant antigens covering the structural proteins of human parvovirus B19 gives a deeper insight into the actual status of infection. In addition, the determination of IgG avidity against these individual recombinant antigens enables a more precise and differentiated picture of the infection event.

Authors+Show Affiliations

Mikrogen molekularbiologische Entwicklungs GmbH, Neuried, Germany. pfrepper@mikrogen.deNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

16316402

Citation

Pfrepper, K-I, et al. "Human Parvovirus B19 Serology and Avidity Using a Combination of Recombinant Antigens Enables a Differentiated Picture of the Current State of Infection." Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health, vol. 52, no. 7-8, 2005, pp. 362-5.
Pfrepper KI, Enders M, Motz M. Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection. J Vet Med B Infect Dis Vet Public Health. 2005;52(7-8):362-5.
Pfrepper, K. I., Enders, M., & Motz, M. (2005). Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection. Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health, 52(7-8), 362-5.
Pfrepper KI, Enders M, Motz M. Human Parvovirus B19 Serology and Avidity Using a Combination of Recombinant Antigens Enables a Differentiated Picture of the Current State of Infection. J Vet Med B Infect Dis Vet Public Health. 2005 Sep-Oct;52(7-8):362-5. PubMed PMID: 16316402.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection. AU - Pfrepper,K-I, AU - Enders,M, AU - Motz,M, PY - 2005/12/1/pubmed PY - 2006/1/7/medline PY - 2005/12/1/entrez SP - 362 EP - 5 JF - Journal of veterinary medicine. B, Infectious diseases and veterinary public health JO - J Vet Med B Infect Dis Vet Public Health VL - 52 IS - 7-8 N2 - In order to improve serodiagnostic methods for the determination of the state of human parovirus B19 infection, a new test system, recomLine Parvovirus, based on the use of recombinant antigens, has been developed and evaluated. The test system combines the advantages of enzyme-linked immunosorbent assay (ELISA) methods with those of the Western blot technique. For the recombinant line assay, five antigens of human parvovirus B19 that were recombinantly produced in Escherichia coli were applied directly on nitrocellulose membranes: VP2, the aminoterminal and the carboxyterminal domain of VP1 (VP-N and VP-C), VP-1S another fragment of VP-N and NS1. In addition, empty virus particles isolated from eukaryotic cell cultures were also applied. The recombinant-line assay was used to detect human IgG and IgM antibodies directed against human parvovirus B19. In addition, the avidity of the IgG antibodies was investigated. The recombinant line assay was evaluated using 87 human serum samples of patients recently infected with human parvovirus B19 including 10 samples of three infection time courses and 100 serum samples of healthy blood donors. All results were compared with commercially available ELISAs. In the case of discrepancies, Western blot analysis was performed. The data revealed the recombinant line assay to be highly sensitive and specific. The individual determination of the human immune response against several recombinant antigens covering the structural proteins of human parvovirus B19 gives a deeper insight into the actual status of infection. In addition, the determination of IgG avidity against these individual recombinant antigens enables a more precise and differentiated picture of the infection event. SN - 0931-1793 UR - https://www.unboundmedicine.com/medline/citation/16316402/Human_parvovirus_B19_serology_and_avidity_using_a_combination_of_recombinant_antigens_enables_a_differentiated_picture_of_the_current_state_of_infection_ L2 - https://doi.org/10.1111/j.1439-0450.2005.00874.x DB - PRIME DP - Unbound Medicine ER -